Antoine Papiernik, Managing Partner: How Sofinnova Partners achieve high returns through taking calculated risks.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Antoine Papiernik, Managing Partner: How Sofinnova Partners achieve high returns through taking calculated risks.
Released on: July 09, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Sofinnova invest early in projects with disruptive technologies that have the potential to become strong sustainable companies with the potential to return in excess of 10x their investment.
  • Summary
  • Transcript
  • Participants
  • Company
Sofinnova invest early in projects with disruptive technologies that have the potential to become strong sustainable companies with the potential to return in excess of 10x their investment. Antoine Papiernik, Managing Partner, Sofinnova Partners explains their investment strategy to PharmaVentures' Fintan Walton and discusses why they are convinced that in every success, human factors are decisive.
Sofinnova invest early in projects with disruptive technologies that have the potential to become strong sustainable companies with the potential to return in excess of 10x their investment. Antoine Papiernik, Managing Partner, Sofinnova Partners explains their investment strategy to PharmaVentures' Fintan Walton and discusses why they are convinced that in every success, human factors are decisive.
Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, Auris, ProQR, NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the Zürich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology). He has also invested in and is a board member of private companies ReCor, MD Start, Shockwave Medical, and Reflexion Medical and ProQR. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. In 2012 and 2011, Antoine was selected by Forbes for its “Midas List” of the world’s top venture capital investors. Antoine is one of the only Europeans on the list, and one of the few life science investors as well.
Sofinnova Partners invests in start-ups, early-stage companies, corporate spin-offs and occasionally restarts. Our focus is on life sciences. We proactively source deals, take a lead role, we are most often the first institutional investor in Round A financings, and we lead our portfolio companies until exit. We sit on the boards of our portfolio companies and play an active role as from the formation phase alongside our entrepreneurs. Sofinnova invests throughout Europe from our headquarters in Paris with a portion of our investments made in the rest of the world.